Replies to post #147107 on Biotech Values

[bladerunner1717]

re: ARRY and AZN

McBio,

Very recently Squarer had talked about the complementary approaches of AZN and NVS with their respective MEK inhibitors; AZN, said Squarer, was more interested in combining their MEK inhibitor with a chemotherapeutic and NVS, on the other hand, was more interested in combining their MEK inhibitor with other targeted therapies. Now, shortly after saying this, ARRY goes out and starts testing the MEK inhibitor partnered with NVS with a chemotherapeutic agent. Don't you think this might have raised some eyebrows at AZN? Yeah, I don't expect AZN to share ANY info with ARRY.


Bladerunner